Page 27 - Confidence Interval News Today

1. In this observational study, idiopathic CD4 lymphocytopenia (ICL) was associated with an increased risk of opportunistic infections, malignancy, and poor response to coronavirus disease 2019 (COVID-19) vaccination. 2. The most common opportunistic infections were related to human papillomavirus, cryptococcosis, molluscum contagiosum, and nontuberculosis mycobacterial disease. Evidence Rating Level: 2 (Good) Study Rundown: CD4 T-cell

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 Investor Relations: Raychel... | June 5, 2023

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient... | June 4, 2023

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needsLate-breaking data to be presented during the 2023 American Society of Clinical Oncology...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...

1. In this randomized controlled trial, an epicutaneous patch containing peanut protein was more effective than a placebo in raising the threshold dose required to trigger an allergic reaction to peanuts in toddlers. 2. The epicutaneous immunotherapy patch was associated with higher rates of treatment-related anaphylaxis than the placebo. Evidence Rating Level: 1 (Excellent) Study

1. In this retrospective cohort study, glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of major adverse cardiac events (MACE) in veterans with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). 2. The addition of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) was not associated with a primary reduction in major adverse cardiac

1. In this retrospective study, tecovirimat was effective for treating mpox regardless of human immunodeficiency virus (HIV) status. 2. The incidence of adverse events was low regardless of HIV status in patients with severe mpox. Evidence Rating Level: 2 (Good) Study Rundown: Mpox is a zoonotic orthopoxvirus first described in the 1950s-1970s. In May 2022,

1. In this randomized controlled trial, respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) prevented RSV-associated lower respiratory tract illness in adults 60+ years of age. 2. The RSVpreF vaccine also was associated with significantly decreased rates of acute respiratory illness in adults aged 60+. Evidence Rating Level: 1 (Excellent) Study Rundown: RSV is a common cause